Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/SNRNP200_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/SNRNP200_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SNRNP200_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/SNRNP200_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SNRNP200_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/SNRNP200_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/SNRNP200_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SNRNP200_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007182618 | Prostate | BPH | ribonucleoprotein complex subunit organization | 87/3107 | 227/18723 | 2.63e-15 | 4.07e-13 | 87 |
GO:002261818 | Prostate | BPH | ribonucleoprotein complex assembly | 85/3107 | 220/18723 | 3.16e-15 | 4.55e-13 | 85 |
GO:00016499 | Prostate | BPH | osteoblast differentiation | 75/3107 | 229/18723 | 1.29e-09 | 5.57e-08 | 75 |
GO:00015039 | Prostate | BPH | ossification | 107/3107 | 408/18723 | 4.31e-07 | 8.83e-06 | 107 |
GO:00002455 | Prostate | BPH | spliceosomal complex assembly | 24/3107 | 79/18723 | 1.69e-03 | 9.75e-03 | 24 |
GO:000838019 | Prostate | Tumor | RNA splicing | 153/3246 | 434/18723 | 9.15e-20 | 5.79e-17 | 153 |
GO:002261319 | Prostate | Tumor | ribonucleoprotein complex biogenesis | 159/3246 | 463/18723 | 3.17e-19 | 1.52e-16 | 159 |
GO:000037518 | Prostate | Tumor | RNA splicing, via transesterification reactions | 119/3246 | 324/18723 | 3.40e-17 | 1.06e-14 | 119 |
GO:000037718 | Prostate | Tumor | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 117/3246 | 320/18723 | 9.31e-17 | 2.22e-14 | 117 |
GO:000039818 | Prostate | Tumor | mRNA splicing, via spliceosome | 117/3246 | 320/18723 | 9.31e-17 | 2.22e-14 | 117 |
GO:007182619 | Prostate | Tumor | ribonucleoprotein complex subunit organization | 91/3246 | 227/18723 | 3.62e-16 | 7.50e-14 | 91 |
GO:002261819 | Prostate | Tumor | ribonucleoprotein complex assembly | 89/3246 | 220/18723 | 3.94e-16 | 7.89e-14 | 89 |
GO:000164915 | Prostate | Tumor | osteoblast differentiation | 77/3246 | 229/18723 | 1.55e-09 | 7.26e-08 | 77 |
GO:000150314 | Prostate | Tumor | ossification | 109/3246 | 408/18723 | 1.13e-06 | 2.14e-05 | 109 |
GO:000024512 | Prostate | Tumor | spliceosomal complex assembly | 26/3246 | 79/18723 | 5.68e-04 | 4.11e-03 | 26 |
GO:000838027 | Skin | AK | RNA splicing | 111/1910 | 434/18723 | 1.85e-20 | 5.49e-17 | 111 |
GO:002261328 | Skin | AK | ribonucleoprotein complex biogenesis | 108/1910 | 463/18723 | 8.48e-17 | 6.27e-14 | 108 |
GO:000037526 | Skin | AK | RNA splicing, via transesterification reactions | 85/1910 | 324/18723 | 1.16e-16 | 7.62e-14 | 85 |
GO:000037726 | Skin | AK | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 84/1910 | 320/18723 | 1.69e-16 | 9.11e-14 | 84 |
GO:000039826 | Skin | AK | mRNA splicing, via spliceosome | 84/1910 | 320/18723 | 1.69e-16 | 9.11e-14 | 84 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SNRNP200 | SNV | Missense_Mutation | novel | c.3157N>C | p.Glu1053Gln | p.E1053Q | O75643 | protein_coding | deleterious(0.01) | benign(0.403) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
SNRNP200 | SNV | Missense_Mutation | | c.2116N>A | p.Glu706Lys | p.E706K | O75643 | protein_coding | deleterious(0) | benign(0.094) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
SNRNP200 | SNV | Missense_Mutation | rs867274085 | c.3131N>G | p.Val1044Gly | p.V1044G | O75643 | protein_coding | deleterious(0) | benign(0.378) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
SNRNP200 | SNV | Missense_Mutation | novel | c.2000T>G | p.Val667Gly | p.V667G | O75643 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | | SD |
SNRNP200 | SNV | Missense_Mutation | novel | c.3613N>C | p.Thr1205Pro | p.T1205P | O75643 | protein_coding | deleterious(0) | benign(0.285) | TCGA-A8-A07W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | exemestane | SD |
SNRNP200 | SNV | Missense_Mutation | rs747218822 | c.1864N>A | p.Asp622Asn | p.D622N | O75643 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
SNRNP200 | SNV | Missense_Mutation | | c.5377C>G | p.Leu1793Val | p.L1793V | O75643 | protein_coding | tolerated(0.14) | benign(0.175) | TCGA-AN-A041-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SNRNP200 | SNV | Missense_Mutation | novel | c.879N>T | p.Leu293Phe | p.L293F | O75643 | protein_coding | deleterious(0) | benign(0.234) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SNRNP200 | SNV | Missense_Mutation | | c.2692C>T | p.Pro898Ser | p.P898S | O75643 | protein_coding | tolerated(0.06) | benign(0.006) | TCGA-AN-A0XP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
SNRNP200 | SNV | Missense_Mutation | | c.4201N>G | p.Leu1401Val | p.L1401V | O75643 | protein_coding | tolerated(0.2) | possibly_damaging(0.474) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |